Annotation Detail
Information
- Associated Genes
- BRAF
- Associated Variants
-
BRAF MUTATION
BRAF MUTATION - Associated Disease
- gastrointestinal stromal tumor
- Source Database
- CIViC Evidence
- Description
- This phase II clinical trial of regorafenib (NCT01068769) examined the long term safety and efficacy of regorafenib monotherapy in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GISTs) who failed previous treatments with imatinib. One patient's GIST harbored a BRAF exon 15 mutation.This patient experienced progressive disease and a progression free survival of 1.6 months.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/4121
- Gene URL
- https://civic.genome.wustl.edu/links/genes/5
- Variant URL
- https://civic.genome.wustl.edu/links/variants/2650
- Rating
- 2
- Evidence Type
- Predictive
- Disease
- Gastrointestinal Stromal Tumor
- Evidence Direction
- Does Not Support
- Drug
- Regorafenib
- Evidence Level
- C
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 27371698
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Regorafenib | Sensitivity | false |